Introduction {#Sec1}
============

Critically ill patients display in-hospital mortality rates up to 20--40%, \[[@CR1]--[@CR3]\] as well as impaired long-term survival and quality of life \[[@CR4], [@CR5]\]. Most ICU trials investigating outcome focused mostly on short-term survival with little regard for long-term outcome and studied the population of critically ill patients as a whole, neglecting potential differences associated with gender.

Few studies analyzed gender-related differences in short- and long-term mortality of ICU patients and found inconsistent results. A large Swedish ICU study showed that male gender was associated with higher consumption of ICU resources and longer ICU stay, but with similar short-term mortality compared to women \[[@CR6]\]. On the contrary, male gender was associated with improved in-hospital survival in a study on sepsis and septic shock \[[@CR7]\]. Other ICU studies did not find relevant differences in short- and long-term survival between women and men \[[@CR8], [@CR9]\].

Even fewer data are available for gender-related differences in long-term survival after critical illness. Moreover, long-term survival is mostly dependent on the burden of comorbidities after ICU discharge, which may vary across genders, as recently described by our group and others \[[@CR5], [@CR9]\]. Therefore, whether the gender itself or the associated demographic and clinical characteristics may influence the long-term survival of critically ill patients is unknown.

The primary aim of this French and euRopean Outcome reGistry in Intensive Care Unit (FROG-ICU) sub-study was to test the hypothesis that gender is independently associated with long-term survival of critically ill patients.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

FROG-ICU was a prospective, observational, multi-center cohort designed to investigate long-term mortality of critically ill adult patients. The study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki 2002, validated by the corresponding ethical committees and registered on ClinicalTrials.gov (NCT01367093). Patients were recruited from August 2011 to June 2013.

The study design was published previously \[[@CR10]\]. Briefly, all consecutive patients admitted to any of the 28 participating ICUs in 19 hospitals in France and Belgium were screened for eligibility. Inclusion criteria were requirement for invasive mechanical ventilation and/or vasopressor or inotrope drug support for more than 24 h following ICU admission. Exclusion criteria were age less than 18 years, severe head injury, brain death or persistent vegetative state, organ transplantation in the last 12 months and/or lack of social security coverage.

The primary endpoint of this study was 1-year mortality. The secondary endpoint was 28-day mortality.

Statistical analysis {#Sec4}
--------------------

Continuous variables are expressed as median (interquartile range), and nominal variables are expressed as number (percentages). Differences between independent groups were assessed with Wilcoxon rank sum test, Mann--Whitney *U*-test, and Fisher's exact test, as appropriate.

Survival was plotted with the Kaplan--Meier curve, and differences between groups were tested with the log-rank test. Unadjusted and covariate-adjusted Cox proportional hazards models were used to evaluate the association between gender and 1-year mortality, resp. 28-day mortality after ICU admission. The relative hazard is expressed as hazard ratio (HR) with 95% confidence interval (CI). Adjustments were performed for Simplified Acute Physiology Score II (SAPS II), Sequential Organ Failure Assessment (SOFA) score, and Charlson Comorbidity Index (CCI). Subgroup analyses were performed for age (below vs. above the median) and diagnosis groups at ICU admission.

To further reduce the bias related to the difference in baseline characteristics between women and men, the primary and secondary endpoints were investigated in a propensity score-matched cohort.

To create a propensity score on gender, gender was explained by the following clinical variables: age, body mass index, SAPS II, Glasgow coma scale, heart rate, mean blood pressure, temperature, pH, hemoglobin, platelets, white blood count, creatinine, urea at inclusion, diagnosis at inclusion (heart failure/cardiogenic shock/sepsis/neurological disease/hemorrhagic shock/trauma/postoperative), Charlson Comorbidity Index, hypertension, dyslipidemia, diabetes mellitus, smoking status, alcohol status, coronary artery disease, valvular heart disease, chronic heart failure, peripheral vascular disease, prior stroke, cognitive dysfunction, loss of autonomy, chronic obstructive pulmonary disease, chronic liver disease, chronic renal disease, renal replacement therapy, malignancy, human immunodeficiency virus infection, acute respiratory insufficiency, tracheostomy. Ratio for matching was to 1 for 1 (one man associated with one women) with a caliper of 20%, using the "nearest neighbor" method. Standardized difference of mean or prevalence between men and women is calculated for each covariate of propensity score to check whether characteristics between groups are well balanced. Matching was accepted when all standardized differences were smaller than 10%. The matching process significantly reduced differences in baseline characteristics (see Additional file [1](#MOESM1){ref-type="media"}: Figure 1).

The null hypothesis was rejected with an adjusted two-sided *P* value \< 0.05. All statistical analyses were performed using R statistical software (The "R" Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec5}
=======

Patient characteristics during ICU stay {#Sec6}
---------------------------------------

The study included 2087 patients, 726 women and 1361 men (Fig. [1](#Fig1){ref-type="fig"}). Patient characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Women and men had globally similar baseline characteristics (i.e., age, burden of comorbidities, and Charlson Comorbidity Index), similar clinical presentation (i.e., blood pressure, heart rate, use of vasopressors, mechanical ventilation), and similar disease severity, according to SAPS II and SOFA score, as shown in Table [1](#Tab1){ref-type="table"}. Significant differences between women and men were found with respect to some preexisting diseases, ICU referral diagnosis, laboratory parameters at admission, and the need for renal replacement therapy during ICU stay, as shown in Table [1](#Tab1){ref-type="table"}. ICU mortality and length of stay were 21.7% and 12 \[7; 21\] days, respectively, without relevant differences between women and men, as shown in Table [2](#Tab2){ref-type="table"}.Fig. 1Study population of the FROG-ICU cohort Table 1Patient characteristics at ICU admissionPatient characteristicsAll\
*N* = 2087Women\
*N *= 726Men\
*N *= 1361*P* value\*Demographic data Age (year)63 \[51; 74\]63 \[51; 74.8\]63 \[51; 74\]0.59 Body Mass Index (kg/m2)26.5 \[23.1; 30.8\]26 \[22.5; 31.2\]26.6 \[23.5; 30.3\]0.51Comorbidities Hypertension902 (43.3%)319 (43.9%)583 (43%)0.67 Dyslipidaemia412 (19.8%)123 (16.9%)289 (21.3%)0.017 Diabetes melllitus384 (18.4%)121 (16.7%)263 (19.4%)0.13 Coronary artery disease188 (9%)35 (4.8%)153 (11.3%)\< 0.001 Valvular heart disease (severe)82 (3.9%)31 (4.3%)51 (3.8%)0.57 Heart failure153 (7.3%)57 (7.9%)96 (7.1%)0.52 Peripheral vascular disease209 (10%)60 (8.3%)149 (11%)0.05 Prior stroke92 (4.4%)25 (3.4%)67 (4.9%)0.11 COPD273 (13.1%)70 (9.6%)203 (15%)0.001 Chronic kidney disease241 (11.6%)80 (11%)161 (11.9%)0.57 Chronic liver disease158 (7.6%)52 (7.2%)106 (7.8%)0.59 Active malignant tumors281 (13.5%)93 (12.8%)188 (13.9%)0.51 HIV53 (2.5%)12 (1.7%)41 (3%)0.06 Loss of autonomy78 (3.7%)38 (5.2%)40 (2.9%)0.009 Cognitive dysfunction33 (1.6%)13 (1.8%)20 (1.5%)0.58Diagnosis at ICU admission Respiratory disorder89 (4.3%)21 (2.9%)68 (5%)0.017 Trauma536 (25.7%)182 (25.1%)354 (26%) Sepsis/septic shock179 (8.6%)53 (7.3%)126 (9.3%) Neurological disease286 (13.7%)120 (16.5%)166 (12.2%) Cardiac arrest394 (18.9%)142 (19.6%)252 (18.5%) Cardiogenic shock146 (7%)55 (7.6%)91 (6.7%) Hemorrhagic shock110 (5.3%)31 (4.3%)79 (5.8%) Planned surgery165 (7.9%)52 (7.2%)113 (8.3%) Others181 (8.7%)70 (9.6%)111 (8.2%)Vital parameters Temperature (°C)37.2 \[36.7; 37.8\]37.2 \[36.7; 37.7\]37.3 \[36.8; 37.9\]0.001 Mean blood pressure (mmHg)81.3 \[72.3; 92\]81.3 \[72.3; 91.7\]81.2 \[72.3; 92\]0.81 Heart rate (bpm)92 \[78; 106\]92 \[79; 106\]91 \[77; 106\]0.60 Glasgow coma scale14 \[5; 15\]14 \[4; 15\]14 \[5; 15\]0.18Laboratory values at admission Arterial pH7.4 \[7.4; 7.5\]7.4 \[7.4; 7.5\]7.4 \[7.4; 7.5\]0.12 Lactate (mmol/L)1.4 \[1; 2\]1.4 \[1.1; 2\]1.4 \[1; 1.9\]0.09 Leukocytes (G/L)10.9 \[7.6; 16.2\]11.6 \[8.2; 17\]10.6 \[7.4; 15.8\]0.004 Hemoglobin (g/L)100 \[89; 114\]99 \[88; 109\]101 \[90; 117\]\< 0.001 Platelets (G/L)164 \[99; 244\]171 \[98; 257\]162 \[101; 237\]0.15 BUN or Urea (mg/dL)8.4 \[5.2; 14\]7.1 \[4.4; 12.6\]9.1 \[5.6; 14.8\]\< 0.001 Creatinine (mg/dL)84 \[59; 150\]69 \[50; 119\]94 \[66; 165\]\< 0.001 Bilirubin (umol/L)13 \[8; 27\]11 \[7; 21\]14 \[9; 29\]\< 0.001Organ support Vasopressors at admission1502 (72.2%)526 (72.5%)976 (72%)0.84 Ventilation during ICU stay: Invasive1632 (80.3%)561 (79.7%)1071 (80.6%)0.76 Non-invasive316 (15.6%)115 (16.3%)201 (15.1%) RRT during ICU stay480 (23%)137 (18.9%)343 (25.2%)0.001Disease severity scores Charlson score3 \[1; 5\]3 \[1; 5\]3 \[1; 5\]0.15 SAPS II49 \[36; 63\]50 \[35; 62\]48 \[36; 63\]0.85 SOFA score8 \[5; 10\]7 \[5; 10\]8 \[5; 11\]0.12Data presented as median \[interquartile range\] and *P* value obtained with Mann--Whitney *U*-test for continuous variables and as number (percentage) with Fisher's exact test for categorical variables Table 2Patient outcomes in the overall cohort (n=2087)All\
*N* = 2087Women\
*N* = 726Men\
*N* = 1361*P* valueICU length of stay (days)12 \[7; 21\]12 \[7; 21\]13 \[7; 22\]0.58ICU mortality452 (21.7%)143 (19.7%)309 (22.7%)0.1128-day mortality443 (21.3%)139 (19.2%)304 (22.4%)0.091-year mortality767 (36.9%)253 (34.9%)514 (37.9%)0.18Data are presented as number (percentage) or median \[interquartile range\], as appropriate

Primary endpoint (1-year mortality) {#Sec7}
-----------------------------------

No significant difference in 1-year mortality after ICU admission (34.9% vs. 37.9%, *P* = 0.18) was found between women and men, as shown in Table [2](#Tab2){ref-type="table"}. Accordingly, there was no difference in the hazard of death for women compared to men \[HR 0.87 (95% CI 0.72--1.06)\], as shown in Fig. [2](#Fig2){ref-type="fig"}. After multivariable adjustment, no difference in the hazard of death was found \[HR 0.99 (95% CI 0.77--1.28)\], as shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Forest plot for mortality according to gender. The adjustment was performed for SAPS II, SOFA score, and Charlson Comorbidity Index

Similar 1-year survival between women and men was found in a propensity score-matched patient cohort of 506 patients (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Accordingly, the hazard of death at 1 year after ICU admission was similar for women compared to men in the matched cohort \[HR 0.79 (95% CI 0.54--1.14)\], as shown in Fig. [2](#Fig2){ref-type="fig"}.Table 3Patient outcomes in the propensity score-matched cohort (*n* = 506)All\
*N* = 506Women\
*N* = 253Men\
*N* = 253*P* value28-day mortality93 (18.4%)40 (15.8%)53 (21%)0.131-year mortality173 (34.3%)80 (31.6%)93 (36.9%)0.20Data are presented as number (percentage) Fig. 3One-year survival of the propensity score-matched cohort

Secondary endpoint (28-day mortality) {#Sec8}
-------------------------------------

No significant difference in survival was found between women and men at 28 days after ICU admission (19.2% vs. 22.4%, *P* = 0.09), as shown in Table [2](#Tab2){ref-type="table"}. Accordingly, there was no difference in the hazard of death for women compared to men \[HR 0.82 (95% CI 0.65--1.02)\], as shown in Fig. [2](#Fig2){ref-type="fig"}. After multivariable adjustment, no difference in the hazard of death was found \[HR 1.08 (95% CI 0.79--1.47)\], as shown in Fig. [2](#Fig2){ref-type="fig"}.

Consistent results were found in the propensity score-matched cohort of 506 patients (Table [3](#Tab3){ref-type="table"}) with no difference in the hazard of death at 28 days after ICU admission between women and men \[HR 0.70 (95% CI 0.44--1.11)\], as shown in Fig. [2](#Fig2){ref-type="fig"}.

Subgroup analysis {#Sec9}
-----------------

As depicted in Fig. [4](#Fig4){ref-type="fig"}, consistent results with similar survivals of women compared to men at both 1 year and 28 days after ICU admission were found, independently from the diagnosis at ICU admission. Notably, we observed a trend toward reduced hazard of death for older women compared to older men, in particular at 28 days after admission, as shown in Additional file [1](#MOESM1){ref-type="media"}: Figure 2.Fig. 4Subgroup analyses for age and diagnosis group at ICU admission

Discussion {#Sec10}
==========

Few studies analyzed gender-related differences in outcome of critically ill patients and found inconsistent results. This study aimed to test the hypothesis that gender is independently associated with long-term survival in a large, prospective, multi-centric cohort of critically ill patients. We found that women have similar long-term survival after ICU admission, compared to men.

First, the population of our study consisted of critically ill patients with relevant ICU mortality, in line with previous studies. Our study showed that women and men have some relevant differences in ICU referral diagnosis and comorbidities, as previously described and long known \[[@CR11], [@CR12]\]. However, and even more notably, women and men were unexpectedly similar regarding demographic characteristics, clinical presentation, disease severity, and ICU outcomes. Despite these similarities in baseline characteristics and outcome, and the effort to include all consecutive patients fulfilling inclusion criteria, we observed that only one of three patients included in our study was a woman. The reason for this imbalance is unknown but will require further investigations. We might anticipate that a combination of several factors, including gender-related variations in clinical presentation of disease, diverging patients' preferences, and variable attitude of the treating teams, may have led to this imbalanced rate of ICU admissions.

Second, we observed consistently similar survival in women and men at both 28 days and 1 year after ICU admission. Survival remained similar after multivariable adjustment for comorbidities and disease severity and also in the propensity score-matched cohort to obviate difference in baseline characteristics. The impact of gender on prognosis has been thoroughly assessed in cardiology \[[@CR13]--[@CR24]\] and psychiatry \[[@CR25]--[@CR31]\], whereas most previous studies with critically ill patients analyzed the population as a whole, with little regard to gender-related differences and found inconsistent results \[[@CR6]\]. To the best of our knowledge, the present study is the first to assess gender-related differences on long-term outcome of critically ill patients. Our observations are of great interest, since despite potential differences in genetic, hormonal, and immunological factors---as shown in other conditions \[[@CR32], [@CR33]\]---outcomes remain very similar for critically ill patients. Of course, other "non-biological" factors including socioeconomical differences may also have contributed or counterbalanced biological differences. However, a previous study from the FROG-ICU cohort showed a negligible impact of socioeconomic status on survival \[[@CR32]\]. Furthermore, despite that a lacking social security coverage was considered an exclusion criterion, only one patient was excluded from the FROG-ICU cohort for this reason. Further research is needed to explore and distinguish biological from socioeconomical components affecting the long-term outcome of women and men.

From a more clinical point of view, our data support the fact that despite that the gender has been included in several widely used prognostic scores in other fields of medicine \[[@CR33]\], none of the commonly used ICU prognostic scores, such as the Acute Physiology and Chronic Health Evaluation (APACHE) II, Simplified Acute Physiology Score (SAPS) II, Multiple Organ Dysfunction Score (MODS), and Sequential Organ Failure Assessment (SOFA), contain gender parameters, which is likely reasonable. Similar outcome between women and men may support the current practice of consistent treatment of the critical illness independently from the gender or, in light of the still severe prognosis of several diseases (i.e., septic shock, cardiogenic shock), a call for the implementation of precision medicine, with regard to differences beyond the gender. Nevertheless, gender-specific admission rates should be viewed as a potential risk of bias since only one-third of patients recruited in FROG-ICU were female. The male--female ratio in FROG-ICU was slightly more pronounced compared to other studies (Additional file [1](#MOESM1){ref-type="media"}: Table 1). If female gender could possibly bias, clinicians against admitting patients to the ICU a "protective" effect of female sex may have been confounded.

Third, our subgroup analysis showed a trend toward a survival benefit for women among elderly subjects. Very notably, older---and not younger---women seem to have a survival benefit compared to men. This observation challenges the current concept of the beneficial effect of estrogens on the incidence of several diseases and survival. This age-dependent differential impact of gender on the survival of critically ill patients is a novel finding, and the reasons remain to be elucidated.

We acknowledge that this study suffers from several limits. First, the observational nature of the data hinders confirmation of causality. Secondly, our data lack to account for variables with a substantial impact on the reported results, (i.e., socioeconomic status, patient compliance, and overall behavior (e.g., readiness to assume risk) after hospital discharge. Finally, the cause of death after ICU discharge was not registered in the FROG-ICU study.

Conclusion {#Sec11}
==========

Women constituted one-third of the population of critically ill patients and had similar survival at 28 days and 1 year after ICU admission, independently from comorbidities and disease severity in a large, prospective, multi-centric cohort study. Older---and not younger---women may have a survival benefit compared to men. Overall, further research is needed focusing on the outcome before ICU admission, assessment of outcome of pre-hospital patient care targeting ICU referral, and disease prevalence and severity with respect to gender.

Additional file
===============

 {#Sec12}

**Additional file 1.** All figures and tables are originals provided by the statistician (Elodie Féliot).
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